The case for & against
Bull & Bear analysis
Bearish
BioDelivery Sciences International, Inc. (BDSI), prior to its acquisition by Collegium Pharmaceutical, Inc. in March 2022, was a biopharmaceutical company specializing in the development of therapeutic products for pain management and addiction. The company was known for its unique drug delivery technologies aimed at improving patient compliance and outcomes. The acquisition has effectively ended the trading life of BDSI, removing it from stock markets and consolidating its assets within Collegium, which aims to expand its portfolio in the opioids management segment.
Bull says
- ↑Collegium paid $5.60/sh, a 54% premium, signaling confidence
- ↑BDSI’s drug-delivery tech addresses unmet pain-management needs
- ↑Q4 2021 EPS of $0.62 beat analyst forecasts, showing strong operations
- ↑Opioid crisis drives demand for BDSI’s non-addictive therapies
- ↑Integration offers synergies to boost combined revenue potential
Bear says
- ↓BDSI no longer trades; investors must target Collegium shares
- ↓$670 M acquisition faces execution risk in merging operations
- ↓Ongoing opioid scrutiny could restrict BDSI-derived product sales
- ↓Collegium may reallocate resources away from BDSI’s pipeline
- ↓Cash buyout implies market doubts on BDSI standalone growth